CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Dabrafenib Mesylate +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01902173
NCT01902173Phase 2Completed
CompareCT.gov

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer

National Cancer Institute (NCI)·interventional·Posted Jul 18, 2013·Updated Jan 14, 2025

In Brief

A Phase 2 clinical trial evaluating Biopsy, Biospecimen Collection, and 5 other interventions for Hematopoietic and Lymphoid Cell Neoplasm and 8 related conditions. Completed, enrolled 27 participants across 16 sites.

Detailed Summary

This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
CountriesUnited States
CollaboratorsGlaxoSmithKline, Novartis Pharmaceuticals

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 18, 2013
Enrollment StartOct 8, 2013
Primary CompletionMay 16, 2018
Study CompletionDec 23, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 13.0 years ago

Interventions

Biopsyprocedure

Undergo a biopsy

Biospecimen Collectionprocedure

Undergo blood sample collection

Computed Tomographyprocedure

Undergo a CT scan

Dabrafenib Mesylatedrug

Given PO

Magnetic Resonance Imagingprocedure

Undergo MRI

Trametinib Dimethyl Sulfoxidedrug

Given PO

Uprosertibdrug

Given PO